HÄLSA Pharma

Hälsa Pharma is a specialized pharmaceutical company headquartered in Hamburg, Germany, that focuses on the development, registration, and distribution of niche medicinal products and orphan drugs. The company is best known for providing essential therapies for rare diseases, particularly Wilson's disease and cystinuria, through its primary product Metalcaptase (D-penicillamine). In addition to managing its own product portfolio, Hälsa Pharma serves as a strategic partner for international companies, offering expertise in regulatory affairs, pharmacovigilance, and market access within the European Union. Their business model is centered on ensuring the availability of specialized medications for small patient populations that are often overlooked by larger industry players. By maintaining a lean and expert organization, the company successfully navigates the complex legal and medical requirements of the orphan drug sector.